In final draft guidance published today (4 March) NICE has recommended infliximab and adalimumab as treatment options for people with severe, active Crohn’s disease whose condition has not responded to conventional therapy, or who are intolerant of or have contraindications to conventional therapy.
The draft guidance from NICE recommends infliximab and adalimumab as treatment options for adults with severe, active Crohn’s disease that has not responded to conventional treatment, or who are intolerant of or have contraindications to conventional therapy.
Treatment should normally be started with the less expensive drug (taking into account drug administration costs, required dose and product price per dose).
Infliximab is also recommended for adults with active, fistulising Crohn’s disease, and for children and young people aged 6-17 years old with severe, active Crohn’s disease.
Crohn’s disease is a chronic inflammatory condition of unknown cause affecting the gastrointestinal tract (gut). It is estimated that around 60,000 people in the UK have the disease, with approximately 3,000 (5%) having the most severe forms of the condition. The disease causes parts of the gastrointestinal tract to become inflamed, causing diarrhoea, pain in the abdomen, weight loss and tiredness.